DN-108

• Description :

  DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes[1].

• UNSPSC :

  12352100

• Target :

  PPAR

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Metabolic Disease

• Smiles :

  O=C1SC(CC2=CC=C(NC(C3(CC3)C4=CC=CC=C4)=O)C=C2)C(N1)=O

• Molecular Formula :

  C20H18N2O3S

• Molecular Weight :

  366.43

• References & Citations :

  [1]Ueda N, et al. Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5- (4- (1-phenyl-1-cyclopropanecarbonylamino) benzyl) -thiazolidine-2 ,4-dio ne. Arzneimittelforschung. 1998 Jun;48 (6) :651-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PPARγ

• CAS Number :

  [195604-21-8]